

# Sagar Lonial

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6378252/sagar-lonial-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

413  
papers

34,152  
citations

68  
h-index

182  
g-index

430  
ext. papers

40,014  
ext. citations

5.7  
avg. IF

6.41  
L-index

#	Paper	IF	Citations
413	Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice.. <i>Lancet Haematology,the</i> , <b>2022</b> , 9, e162-e165	14.6	2
412	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.. <i>Lancet Haematology,the</i> , <b>2022</b> , 9, e143-e161	14.6	6
411	Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2102257	2.2	3
410	Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients. <i>Blood</i> , <b>2021</b> , 138, 1616-1616	2.2	
409	Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?. <i>Blood</i> , <b>2021</b> , 138, 2746-2746	2.2	1
408	Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial. <i>Blood</i> , <b>2021</b> , 138, 2733-2733	2.2	
407	BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction. <i>Blood</i> , <b>2021</b> , 138, 1624-1624	2.2	
406	Evidence of Improved Knowledge and Skills Among Hematologists/Oncologists Participating in Online CME-Certified Activities. <i>Blood</i> , <b>2021</b> , 138, 4958-4958	2.2	
405	Mitochondrial Electron Transport Chain Inhibition Promotes Resistance to Proteasome Inhibitors in Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 1611-1611	2.2	
404	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR). <i>Blood</i> , <b>2021</b> , 138, 2758-2758	2.2	
403	Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. <i>Blood</i> , <b>2021</b> , 137, 3604-3615	2.2	11
402	Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , <b>2021</b> , 137, 3616-3628	2.2	16
401	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, e105-e118	21.7	32
400	Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1139-1149	2.2	23
399	Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 103	7	10
398	Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 8016-8016	2.2	8
397	Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, 701-710	2	1

396	Selinexor for the treatment of patients with previously treated multiple myeloma. <i>Expert Review of Hematology</i> , <b>2021</b> , 14, 697-706	2.8	3
395	Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. <i>Cancer</i> , <b>2021</b> , 127, 4198-4212	6.4	23
394	YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 464-476	8.9	23
393	Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. <i>American Journal of Hematology</i> , <b>2021</b> , 96, E68-E71	7.1	3
392	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 142-154	21.7	22
391	Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, 46-54.e4	2	3
390	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 705-716	59.2	287
389	Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3178-3189	12.9	1
388	Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor. <i>Clinical Pharmacology: Advances and Applications</i> , <b>2021</b> , 13, 169-180	1.5	1
387	Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. <i>Molecular Cell</i> , <b>2021</b> , 81, 3833-3847.e11	17.6	2
386	Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. <i>Lancet Haematology, the</i> , <b>2021</b> , 8, e794-e807	14.6	4
385	Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
384	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. <i>Blood Cancer Discovery</i> , <b>2021</b> , 2, 600-615	7	2
383	Antibody treatment in multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , <b>2021</b> , 19, 166-174	14	5
382	Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. <i>JCO Oncology Practice</i> , <b>2020</b> , 16, e1169-e1180	2.3	2
381	A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2497-2505	12.9	5
380	Reply to N. Biran et al. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1368-1369	2.2	
379	Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. <i>Nature Communications</i> , <b>2020</b> , 11, 1228	17.4	24

378	Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. <i>Advances in Therapy</i> , <b>2020</b> , 37, 1464-1478	4.1	4
377	DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 3843-3855	12.9	15
376	Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era. <i>Blood</i> , <b>2020</b> , 136, 20-21	2.2	
375	Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 31-32	2.2	
374	Role of clonoSEQ, a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 50-51	2.2	
373	Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study <b>2020</b> , 8,		13
372	Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 47-48	2.2	6
371	Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , <b>2020</b> , 136, 22-23	2.2	1
370	Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , <b>2020</b> , 136, 26-27	2.2	6
369	Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study. <i>Blood</i> , <b>2020</b> , 136, 4-6	2.2	1
368	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. <i>Blood Advances</i> , <b>2020</b> , 4, 181-190	7.8	5
367	DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 8519-8519	2.2	7
366	Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs). <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 8536-8536	2.2	20
365	DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 8541-8541	2.2	4
364	Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. <i>Lancet Haematology</i> , <b>2020</b> , 7, e447-e455	14.6	32
363	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology</i> , <b>2020</b> , 21, 207-221	21.7	281
362	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4030-4041	2.2	25
361	We need CD38 STAT-JAK. <i>Blood</i> , <b>2020</b> , 136, 2246-2248	2.2	

360	Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. <i>Ophthalmology and Therapy</i> , <b>2020</b> , 9, 889-911	5	35
359	Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 1228-1234	8.7	1
358	Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 106	7	20
357	Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2020</b> , 20, 797-803 <sup>2</sup>		3
356	Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 91	7	36
355	Downregulation of PA28 $\beta$ induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 125	7	3
354	Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1126-1137	2.2	88
353	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 40	7	7
352	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1928-1937	2.2	56
351	Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 3	7	26
350	$\beta$ -Phosphogluconolactone, a Byproduct of the Oxidative Pentose Phosphate Pathway, Contributes to AMPK Activation through Inhibition of PP2A. <i>Molecular Cell</i> , <b>2019</b> , 76, 857-871.e9	17.6	15
349	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. <i>Leukemia</i> , <b>2019</b> , 33, 1736-1746	10.7	29
348	Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. <i>Cancer</i> , <b>2019</b> , 125, 2991-3000	6.4	47
347	Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. <i>Nature Communications</i> , <b>2019</b> , 10, 1911	17.4	53
346	Is there still a role for stem cell transplantation in multiple myeloma?. <i>Cancer</i> , <b>2019</b> , 125, 2534-2543	6.4	10
345	Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, 372-380	2	48
344	Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. <i>Cancer Discovery</i> , <b>2019</b> , 9, 756-777	24.4	13
343	Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studies. <i>Cancer</i> , <b>2019</b> , 125, 2322-2324	6.4	

342	Daratumumab in multiple myeloma. <i>Cancer</i> , <b>2019</b> , 125, 2364-2382	6.4	58
341	Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, 332-344	2	13
340	Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models. <i>PLoS ONE</i> , <b>2019</b> , 14, e0206309	3.7	5
339	SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, 537-544	2	15
338	Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 727-738	59.2	266
337	Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. <i>JCI Insight</i> , <b>2019</b> , 5,	9.9	55
336	Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 2431-2445	15.9	16
335	Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 4110-4123	15.9	11
334	Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study. <i>Blood</i> , <b>2019</b> , 134, 1872-1877	2	2
333	Unsupervised Clustering of DNA Copy Number Profiles Identifies a High-Risk Subtype of Hyperdiploid Multiple Myeloma: An MmrF Compass Analysis. <i>Blood</i> , <b>2019</b> , 134, 1805-1805	2.2	1
332	Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 94	7	59
331	Safety and survival outcomes for bloodless transplantation in patients with myeloma. <i>Cancer</i> , <b>2019</b> , 125, 185-193	6.4	3
330	Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. <i>Cancer</i> , <b>2019</b> , 125, 416-423	6.4	22
329	High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , <b>2019</b> , 95, 279-289	4.6	77
328	Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , <b>2019</b> , 184, 475-479	4.5	14
327	Current developments in immunotherapy in the treatment of multiple myeloma. <i>Cancer</i> , <b>2018</b> , 124, 2075-2085	4.2	42
326	The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells. <i>Molecular Cell</i> , <b>2018</b> , 69, 923-937.e8	17.6	8
325	Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. <i>Clinical Pharmacokinetics</i> , <b>2018</b> , 57, 529-538	6.2	18



324	Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy. <i>Cancer Letters</i> , <b>2018</b> , 435, 44-54	9.9	14
323	MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. <i>Cancer Cell</i> , <b>2018</b> , 34, 315-330.e7	24.3	43
322	Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma. <i>Future Oncology</i> , <b>2018</b> , 14, 3111-3121	3.6	8
321	Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone. <i>Blood</i> , <b>2018</b> , 132, 3241-3241	2.2	1
320	Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. <i>Blood</i> , <b>2018</b> , 132, 2157-2157	2.2	1
319	Safety and Efficacy of Evomela In Myeloma Autotransplants. <i>Blood</i> , <b>2018</b> , 132, 3446-3446	2.2	0
318	Efficacy of Induction Therapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , <b>2018</b> , 132, 3294-3294	2.2	2
317	Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8040-8040	2.2	7
316	Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8050-8050	2.2	1
315	Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. <i>Blood</i> , <b>2018</b> , 132, 3302-3302	2.2	
314	Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function. <i>Blood</i> , <b>2018</b> , 132, 951-951	2.2	0
313	Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab. <i>Journal of Oncology Practice</i> , <b>2018</b> , 14, 414-422	3.1	19
312	Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma. <i>Journal of Oncology Practice</i> , <b>2018</b> , 14, 561-564	3.1	3
311	Ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 1949-1968		32
310	Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. <i>Cancer</i> , <b>2018</b> , 124, 4342-4349	6.4	20
309	Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites. <i>Cancer</i> , <b>2018</b> , 124, 4358-4365	6.4	3
308	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. <i>Cancer</i> , <b>2018</b> , 124, 4032-4043	6.4	82
307	Patient-reported outcomes of multiple myeloma patients treated with panobinostat after 2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial. <i>British Journal of Haematology</i> , <b>2018</b> , 181, 628-636	4.5	12

306	Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. <i>Cell Metabolism</i> , <b>2017</b> , 25, 358-373	24.6	83
305	Deacetylase inhibitors: an advance in myeloma therapy?. <i>Expert Review of Hematology</i> , <b>2017</b> , 10, 229-237.	7.8	24
304	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 571-582	4.5	39
303	Academic, Foundation, and Industry Collaboration in Finding New Therapies. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1762-1769	59.2	45
302	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 547-560	4.5	38
301	HMG-CoA synthase 1 is a synthetic lethal partner of BRAF in human cancers. <i>Journal of Biological Chemistry</i> , <b>2017</b> , 292, 10142-10152	5.4	18
300	MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma. <i>Nucleic Acids Research</i> , <b>2017</b> , 45, 2396-2407	20.1	48
299	Autologous hematopoietic transplant in multiple myeloma <b>2017</b> , 194-206		
298	Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. <i>Blood</i> , <b>2017</b> , 130, 974-981	2.2	312
297	Role of F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, e206-e217	21.7	275
296	Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment. <i>Clinical Pharmacokinetics</i> , <b>2017</b> , 56, 915-924	6.2	46
295	Safety of proteasome inhibitors for treatment of multiple myeloma. <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 167-183	4.1	29
294	Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent. <i>Expert Review of Hematology</i> , <b>2017</b> , 10, 933-939	2.8	8
293	Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 896-905	4.5	101
292	High-risk Multiple Myeloma: Definition and Management. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2017</b> , 17S, S80-S87	2	26
291	A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma. <i>Cancer</i> , <b>2017</b> , 123, 4617-4630	6.4	32
290	Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 66-74	4.5	12
289	Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. <i>Pharmacological Research</i> , <b>2017</b> , 117, 185-191	10.2	19



288	Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. <i>Blood Advances</i> , <b>2017</b> , 1, 2105-2114	7.8	103
287	CD86 regulates myeloma cell survival. <i>Blood Advances</i> , <b>2017</b> , 1, 2307-2319	7.8	9
286	Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , <b>2016</b> , 16, 1291-301	5.4	10
285	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, e328-e346	21.7	1155
284	HLA polymorphism and risk of multiple myeloma. <i>Leukemia</i> , <b>2016</b> , 30, 2260-2264	10.7	16
283	Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth. <i>Molecular Cell</i> , <b>2016</b> , 64, 859-874	17.4	42
282	New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5959-5965	12.9	29
281	Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. <i>Cancer Biology and Therapy</i> , <b>2016</b> , 17, 769-77	4.6	11
280	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , <b>2016</b> , 12, 1-222	10.2	3838
279	Gene integrated set profile analysis: a context-based approach for inferring biological endpoints. <i>Nucleic Acids Research</i> , <b>2016</b> , 44, e69	20.1	9
278	Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. <i>Lancet, The</i> , <b>2016</b> , 387, 1551-1560	40	581
277	Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. <i>Expert Review of Clinical Pharmacology</i> , <b>2016</b> , 9, 35-48	3.8	19
276	Bayesian Network Models of Multiple Myeloma: Drivers of High Risk and Durable Response. <i>Blood</i> , <b>2016</b> , 128, 4406-4406	2.2	5
275	New Targets and New Agents in High-Risk Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2016</b> , 36, e431-e441	7.1	9
274	Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation. <i>Oncotarget</i> , <b>2016</b> , 7, 59727-59741	3.3	18
273	BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. <i>Oncotarget</i> , <b>2016</b> , 7, 27753-63	3.3	15
272	New Targets and New Agents in High-Risk Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2016</b> , 35, e431-41	7.1	11
271	Emerging treatments in Castleman disease - a critical appraisal of siltuximab. <i>Biologics: Targets and Therapy</i> , <b>2016</b> , 10, 9-15	4.4	3

270	Monoclonal Antibodies for the Treatment of Myeloma: Targeting SLAMF7 and CD38. <i>Cancer Journal (Sudbury, Mass )</i> , <b>2016</b> , 22, 3-6	2.2	6
269	How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4421-4430	2.2	15
268	Myeloma Is Not a Single Disease. <i>Journal of Oncology Practice</i> , <b>2016</b> , 12, 287-92	3.1	9
267	Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2016</b> , 16, 466-471.e1	2	29
266	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , <b>2016</b> , 127, 2955-62	2.2	463
265	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. <i>Blood</i> , <b>2016</b> , 128, 37-44	2.2	272
264	Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. <i>Blood</i> , <b>2016</b> , 127, 713-21	2.2	99
263	Treatment of MM: Upcoming Novel Therapies. <i>Cancer Treatment and Research</i> , <b>2016</b> , 169, 195-205	3.5	2
262	Panobinostat for the treatment of multiple myeloma. <i>Expert Opinion on Orphan Drugs</i> , <b>2015</b> , 3, 229-238	1.1	2
261	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2863-9	2.2	976
260	Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 737-48	3.5	43
259	Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. <i>Molecular Cell</i> , <b>2015</b> , 59, 345-358	17.6	91
258	Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2015</b> , 15, 514-8	2	3
257	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. <i>Nature Cell Biology</i> , <b>2015</b> , 17, 1484-96	23.4	153
256	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 2039-2051	4.7	114
255	Novel combination approaches for myeloma. <i>Hematology American Society of Hematology Education Program</i> , <b>2015</b> , 2015, 286-93	3.1	4
254	How I treat high-risk myeloma. <i>Blood</i> , <b>2015</b> , 126, 1536-43	2.2	66
253	Treatment options for relapsed and refractory multiple myeloma. <i>Blood</i> , <b>2015</b> , 125, 3085-99	2.2	116

252	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , <b>2015</b> , 125, 2068-74	2.2	426
251	A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , <b>2015</b> , 171, 539-46	4.5	11
250	Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. <i>Transfusion</i> , <b>2015</b> , 55, 2351-7	2.9	3
249	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 621-31	59.2	935
248	Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. <i>Lancet Haematology</i> , <b>2015</b> , 2, e516-27	14.6	129
247	New cancers after autotransplantations for multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 738-45	4.7	28
246	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study). <i>Blood</i> , <b>2015</b> , 126, 1827-1827	2.2	10
245	Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up. <i>Blood</i> , <b>2015</b> , 126, 28-28	2.2	22
244	Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , <b>2015</b> , 126, 29-29	2.2	6
243	A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). <i>Blood</i> , <b>2015</b> , 126, 3036-3036	2.2	10
242	Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis. <i>Blood</i> , <b>2015</b> , 126, 4222-4222	2.2	13
241	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promising Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study). <i>Blood</i> , <b>2015</b> , 126, 4228-4228	2.2	17
240	Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective. <i>Blood</i> , <b>2015</b> , 126, 4254-4254	2.2	2
239	Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , <b>2015</b> , 126, 508-508	2.2	30
238	ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 8508-8508	2.2	12
237	Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 8526-8526	2.2	5
236	Phase II study of daratumumab (DARA) monotherapy in patients with $\geq$ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, LBA8512-LBA8512	2.2	4
235	The AFFIRM Study: A multicenter phase 2 study of single-agent filanesib (ARRY-520) in patients with advanced multiple myeloma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS8613-TPS8613	2.2	2

234	Phase II study of daratumumab (DARA) monotherapy in patients with B lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, LBA8512-LBA8512	2.2	14
233	Bloodless transplants for multiple myeloma are feasible and yield similar results as matched controls.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e19538-e19538	2.2	
232	Analysis of outcomes based on response for patients with relapsed or relapsed and refractory multiple myeloma in the phase 3 PANORAMA 1 study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 8575-8575	2.2	
231	A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. <i>Blood</i> , <b>2014</b> , 123, 1461-9	2.2	152
230	Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex. <i>Molecular Cell</i> , <b>2014</b> , 53, 534-48	17.6	184
229	Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. <i>Cancer Cell</i> , <b>2014</b> , 25, 91-101	24.3	657
228	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , <b>2014</b> , 15, 333-42	21.7	206
227	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , <b>2014</b> , 15, e538-48	21.7	2253
226	Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2014</b> , 14, 356-69	2	6
225	Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth. <i>Molecular Cell</i> , <b>2014</b> , 55, 552-65	17.6	78
224	Relapsed and refractory multiple myeloma: new therapeutic strategies. <i>Hematology/Oncology Clinics of North America</i> , <b>2014</b> , 28, 861-90	3.1	2
223	Older patients with myeloma derive similar benefit from autologous transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 1796-803	4.7	66
222	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , <b>2014</b> , 15, 1195-206	21.7	604
221	Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 852-857	4.7	25
220	Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 402-408.e1	4.7	79
219	MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. <i>Blood</i> , <b>2014</b> , 123, 3269-76	2.2	59
218	The Tao of myeloma. <i>Blood</i> , <b>2014</b> , 124, 1873-9	2.2	42
217	Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. <i>Blood</i> , <b>2014</b> , 123, 1826-32	2.2	271

216	Down to the bitter end. <i>Blood</i> , <b>2014</b> , 123, 3061-2	2.2	2
215	Integrated analysis of whole-genome paired-end and mate-pair sequencing data for identifying genomic structural variations in multiple myeloma. <i>Cancer Informatics</i> , <b>2014</b> , 13, 49-53	2.4	16
214	Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. <i>Blood</i> , <b>2014</b> , 124, 1038-46	2.2	171
213	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. <i>Lancet Oncology</i> , <b>2014</b> , 15, 1503-1512	21.7	207
212	Novel drug combinations for the management of relapsed/refractory multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2014</b> , 14 Suppl, S71-7	2	11
211	Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2014</b> , 14, e59-63	2	3
210	Current strategies for treatment of relapsed/refractory multiple myeloma. <i>Expert Review of Hematology</i> , <b>2014</b> , 7, 97-111	2.8	58
209	Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , <b>2014</b> , 124, 2128-2129	2.2	4
208	Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2014</b> , 124, 302-302	2.2	11
207	Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial. <i>Blood</i> , <b>2014</b> , 124, 32-32	2.2	10
206	MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability of Pomalidomide + Low-Dose Dexamethasone in Patients with Relapsed or Refractory and Refractory Multiple Myeloma and Renal Impairment. <i>Blood</i> , <b>2014</b> , 124, 4730-4730	2.2	4
205	Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM). <i>Blood</i> , <b>2014</b> , 124, 4764-4764	2.2	10
204	Interim Analysis of the MmrF Commpass Trial: Identification of Novel Rearrangements Potentially Associated with Disease Initiation and Progression. <i>Blood</i> , <b>2014</b> , 124, 722-722	2.2	13
203	Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 8510-8510	2.2	9
202	Ablation of CD28-86 Signaling Results in Induction of Both Caspase-Dependent and Caspase-Independent Cell Death in Myeloma Cells. <i>Blood</i> , <b>2014</b> , 124, 4726-4726	2.2	
201	A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and pralixfor as a mobilization regimen for patients with lymphoma. <i>Transfusion</i> , <b>2013</b> , 53, 76-84	2.9	3
200	Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 370-6	2	39
199	Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13, 1731-40	5.4	28



198	Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences. <i>Annals of Pharmacotherapy</i> , <b>2013</b> , 47, 1136-42	2.9	26
197	Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 657-63	2	10
196	Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials. <i>Cancer</i> , <b>2013</b> , 119, 4119-28	6.4	33
195	The future of drug development and therapy in myeloma. <i>Seminars in Oncology</i> , <b>2013</b> , 40, 652-8	5.5	6
194	Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial. <i>Biology of Blood and Marrow</i>	4.7	17
193	Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. <i>Lancet Oncology</i> , <b>2013</b> , 14, 1129-1140	21.7	189
192	Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. <i>Haematologica</i> , <b>2013</b> , 98, 1753-61	6.6	267
191	Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib. <i>Biologics: Targets and Therapy</i> , <b>2013</b> , 7, 13-32	4.4	12
190	PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. <i>Blood</i> , <b>2013</b> , 122, 2331-7	2.2	255
189	Induction therapy for newly diagnosed multiple myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2013</b> , 11, 19-28	7.3	7
188	Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , <b>2013</b> , 41	2.6	
187	Transcriptional and Post-Translational Regulation Of The Bcl-2 Family By IL-6 Mediates Resistance To ABT-737 In Multiple Myeloma. <i>Blood</i> , <b>2013</b> , 122, 1924-1924	2.2	2
186	MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , <b>2013</b> , 122, 1969-1969	2.2	11
185	Prolonged Survival and Improved Response Rates With ARRY-520 In Relapsed/Refractory Multiple Myeloma (RRMM) Patients With Low Hb Acid Glycoprotein (AAG) Levels: Results From a Phase 2 Study. <i>Blood</i> , <b>2013</b> , 122, 285-285	2.2	13
184	Changing Epidemiology and Improved Survival In Patients With Waldenstrom Macroglobulinemia: Review Of Surveillance, Epidemiology, and End Results (SEER) Data. <i>Blood</i> , <b>2013</b> , 122, 3135-3135	2.2	6
183	ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM). <i>Blood</i> , <b>2013</b> , 122, 759-759	2.2	14
182	Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8517-8517	2.2	6
181	Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8532-8532	2.2	3



180	Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8540-8540	2.2	1
179	Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8542-8542	2.2	10
178	MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8584-8584	2.2	2
177	Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8588-8588	2.2	0
176	Survival outcomes of plasma cell leukemia (PCL) in the United States: A SEER analysis.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8609-8609	2.2	1
175	Outcomes of hematopoietic stem cell transplant recipients admitted to the medical intensive care unit.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 7035-7035	2.2	
174	Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8531-8531	2.2	
173	AKT inhibitors in multiple myeloma <b>2013</b> , 104-113		
172	Correlation Among Different Plasma Cell Disorders Markers and Immunoglobulin Heavy Light Chains (HLC). <i>Blood</i> , <b>2013</b> , 122, 3148-3148	2.2	
171	An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. <i>Blood</i> , <b>2012</b> , 119, 5661-70	2.2	209
170	A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. <i>Blood</i> , <b>2012</b> , 120, 2817-25	2.2	544
169	Sequential or combination therapy for multiple myeloma. <i>Expert Review of Hematology</i> , <b>2012</b> , 5, 533-45	2.8	5
168	An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2012</b> , 12, 310-8	2	97
167	Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 725-7	1.9	3
166	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. <i>Leukemia</i> , <b>2012</b> , 26, 149-57	10.7	580
165	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , <b>2012</b> , 8, 445-544	4.2	2783
164	Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 1820-3	1.9	103
163	Recovery and rebound of platelet counts in mice after thrombocytopenia induced by combination bortezomib + romidepsin. <i>Experimental Hematology</i> , <b>2012</b> , 40, 95-6	3.1	1

162	Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1953-9	2.2	244
161	PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma. <i>Blood</i> , <b>2012</b> , 120, 1852-1852	2.2	4
160	A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results. <i>Blood</i> , <b>2012</b> , 120, 202-202	2.2	12
159	The Multiple Myeloma Research Foundation (MMRF) CoMMpassSM Study: A Longitudinal Study in Newly-Diagnosed Multiple Myeloma Patients to Assess Genomic Profiles, Immunophenotypes and Clinical Outcomes. <i>Blood</i> , <b>2012</b> , 120, 3980-3980	2.2	1
158	Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study. <i>Blood</i> , <b>2012</b> , 120, 4061-4061	2.2	11
157	Phase II Trial of Initial Safety and Toxicity Prior to the Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated by the Eastern Cooperative Oncology Group. <i>Blood</i> , <b>2012</b> , 120, 4079-4079	2.2	1
156	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis. <i>Blood</i> , <b>2012</b> , 120, 450-450	2.2	8
155	Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e18572-e18572	2.2	4
154	Prioritizing Content in Continuing Hematologic Oncology Education: A Survey of 51 Clinical Investigators. <i>Blood</i> , <b>2012</b> , 120, 4270-4270	2.2	
153	Inhibition of Heat Shock Factor 1 (HSF1) Is More Effective At Sensitizing Myeloma Cells to Bortezomib Than Inhibition of Individual HSF1 Targets.. <i>Blood</i> , <b>2012</b> , 120, 2953-2953	2.2	
152	Pre-Transplant Salvage Therapy Prior to Autologous Transplant (AHCT) in Patients Not Responding to Initial Induction for Multiple Myeloma (MM). <i>Blood</i> , <b>2012</b> , 120, 597-597	2.2	
151	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. <i>Blood</i> , <b>2011</b> , 117, 4691-5	2.2	681
150	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , <b>2011</b> , 117, 6063-73	2.2	234
149	Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. <i>Blood</i> , <b>2011</b> , 118, 535-43	2.2	70
148	Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. <i>British Journal of Haematology</i> , <b>2011</b> , 153, 729-40	4.5	84
147	Initial genome sequencing and analysis of multiple myeloma. <i>Nature</i> , <b>2011</b> , 471, 467-72	50.4	1117
146	Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 67, 57-67	3.5	83
145	Is subcutaneous bortezomib ready for prime time?. <i>Current Hematologic Malignancy Reports</i> , <b>2011</b> , 6, 73-4	4.4	4

144	Putting the E (evidence) in a new Era for myeloma. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 349-50	1.9	
143	Farnesyl transferase inhibitors, autophagy, and proteasome inhibition: synergy for all the right reasons. <i>Autophagy</i> , <b>2011</b> , 7, 448-9	10.2	4
142	Treatment options for relapsed and refractory multiple myeloma. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 1264-77	12.9	103
141	Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4243-9	2.2	107
140	Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis. <i>Blood</i> , <b>2011</b> , 118, 1855-1855	2.2	4
139	ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study. <i>Blood</i> , <b>2011</b> , 118, 1860-1860	2.2	5
138	Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis. <i>Blood</i> , <b>2011</b> , 118, 1876-1876	2.2	10
137	Renal Function Measures Improve on Lenalidomide and Dexamethasone and Compete with Patient Characteristics to Predict Lenalidomide Dose Density and Hematologic Toxicity: An E4A03 Analysis. <i>Blood</i> , <b>2011</b> , 118, 1882-1882	2.2	1
136	Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study. <i>Blood</i> , <b>2011</b> , 118, 301-301	2.2	5
135	A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2011</b> , 118, 303-303	2.2	4
134	BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2011</b> , 118, 305-305	2.2	24
133	Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,. <i>Blood</i> , <b>2011</b> , 118, 3959-3959	2.2	1
132	Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 23 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study,. <i>Blood</i> , <b>2011</b> , 118, 3968-3968	2.2	1
131	Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,. <i>Blood</i> , <b>2011</b> , 118, 3976-3976	2.2	10
130	The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs),. <i>Blood</i> , <b>2011</b> , 118, 3994-3994	2.2	2
129	Second Autologous Transplants for Multiple Myeloma (MM) Relapse After a Prior Autologous Transplant (AHCT) Report From the Center for International Blood and Marrow Transplant Research (CIBMTR). <i>Blood</i> , <b>2011</b> , 118, 504-504	2.2	3
128	Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results. <i>Blood</i> , <b>2011</b> , 118, 634-634	2.2	5
127	Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial. <i>Blood</i> , <b>2011</b> , 118, 811-811	2.2	9

126	Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2). <i>Blood</i> , <b>2011</b> , 118, 814-814	2.2	9
125	Second Transplants in Relapsed Multiple Myeloma (MM): Autologous (AHCT) Versus Non-Myeloablative/Reduced Intensity (NST/RIC) Allogeneic Transplantation (AlloHCT). <i>Blood</i> , <b>2011</b> , 118, 824-824	2.2	1
124	The Use of Bortezomib in Autologous Transplantation for Multiple Myeloma <b>2011</b> , 69-77		
123	Truncation of NF-KB2 Is Associated with Poor Response to Bortezomib Treatment in Multiple Myeloma. <i>Blood</i> , <b>2011</b> , 118, 2891-2891	2.2	
122	Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis. <i>Blood</i> , <b>2011</b> , 118, 1959-1959	2.2	
121	Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial. <i>Blood</i> , <b>2011</b> , 118, 2988-2988	2.2	
120	Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study. <i>Blood</i> , <b>2011</b> , 118, 1875-1875	2.2	
119	Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial. <i>Blood</i> , <b>2011</b> , 118, 815-815	2.2	
118	The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM). <i>Blood</i> , <b>2011</b> , 118, 2935-2935	2.2	1
117	Bone Marrow Stromal Cells Enforce MCL-1 Dependence In Multiple Myeloma Through the Secretion of A Soluble Factor,. <i>Blood</i> , <b>2011</b> , 118, 3950-3950	2.2	0
116	ETV1 Is a Survival Gene That Is Expressed in a Subset of Multiple Myeloma. <i>Blood</i> , <b>2011</b> , 118, 2884-2884	2.2	
115	The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development. <i>Blood</i> , <b>2011</b> , 118, 1024-1024	2.2	
114	Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes. <i>Blood</i> , <b>2011</b> , 118, 1377-1377	2.2	
113	Validation of the Function of 14-3-3 $\beta$ In Multiple Myeloma (MM). <i>Blood</i> , <b>2011</b> , 118, 1369-1369	2.2	
112	MLN4924, An Investigational NAE Inhibitor, Suppresses AKT and mTOR Signaling Pathway Through up Regulating REDD1 in Human Myeloma Cells. <i>Blood</i> , <b>2011</b> , 118, 1870-1870	2.2	
111	Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma. <i>Oncology</i> , <b>2011</b> , 25 Suppl 2, 25-31	1.8	4
110	A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 5079-86	12.9	82
109	Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. <i>Blood</i> , <b>2010</b> , 116, 679-86	2.2	680

108	Relapsed multiple myeloma. <i>Hematology American Society of Hematology Education Program</i> , <b>2010</b> , 2010, 303-9	3.1	33
107	Presentation and risk stratification--improving prognosis for patients with multiple myeloma. <i>Cancer Treatment Reviews</i> , <b>2010</b> , 36 Suppl 2, S12-7	14.4	14
106	Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation. <i>Hematology American Society of Hematology Education Program</i> , <b>2010</b> , 2010, 310-3	3.1	9
105	The White House crusade against ... MGUS?. <i>Blood</i> , <b>2010</b> , 116, 1020-1	2.2	
104	Future directions in immunomodulatory therapy. <i>Medical Oncology</i> , <b>2010</b> , 27 Suppl 1, S62-6	3.7	0
103	Improving induction therapy in multiple myeloma. <i>Current Hematologic Malignancy Reports</i> , <b>2010</b> , 5, 119-28	4	
102	Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. <i>Cancer</i> , <b>2010</b> , 116, 3143-51	6.4	27
101	Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial. <i>Blood</i> , <b>2010</b> , 116, 1937-1937	2.2	1
100	Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program. <i>Blood</i> , <b>2010</b> , 116, 1952-1952	2.2	2
99	Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM). <i>Blood</i> , <b>2010</b> , 116, 1954-1954	2.2	6
98	A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2010</b> , 116, 1959-1959	2.2	4
97	Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM). <i>Blood</i> , <b>2010</b> , 116, 3031-3031	2.2	3
96	Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM). <i>Blood</i> , <b>2010</b> , 116, 985-985	2.2	6
95	Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study. <i>Blood</i> , <b>2010</b> , 116, 986-986	2.2	3
94	Responses and Survival Are Not Affected by Cytogenetics In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM) Treated with Single-Agent Carfilzomib. <i>Blood</i> , <b>2010</b> , 116, 1942-1942	2.2	
93	High Dose Intravenous Busulfan (BU) and Melphalan (MEL) Followed by Bortezomib (BTZ) as Conditioning with Autologous Peripheral Blood Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (MM). <i>Blood</i> , <b>2010</b> , 116, 1355-1355	2.2	
92	Leukemogenic Tyrosine Kinases Inhibit PKM2 to Promote the Warburg Effect and Tumor Growth. <i>Blood</i> , <b>2010</b> , 116, 3142-3142	2.2	
91	Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle. <i>Blood</i> , <b>2010</b> , 116, 1963-1963	2.2	0



90	Thrombocytopenia Induced by Combination Administration of Romidepsin and Bortezomib In Mice Is Rapidly Reversible After Drug Treatment. <i>Blood</i> , <b>2010</b> , 116, 4909-4909	2.2	
89	Frontline regimens for multiple myeloma patients. <i>Clinical Advances in Hematology and Oncology</i> , <b>2010</b> , 8, 331-2	0.6	
88	Supportive therapies in multiple myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2009</b> , 7, 971-9	7.3	3
87	Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3518-25	2.2	213
86	Treatment of relapsed and refractory myeloma. <i>Current Hematologic Malignancy Reports</i> , <b>2009</b> , 4, 99-107	4.4	5
85	Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. <i>British Journal of Haematology</i> , <b>2009</b> , 144, 895-903	4.5	252
84	Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , <b>2009</b> , 145, 681-708	4.5	26
83	Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.. <i>Blood</i> , <b>2009</b> , 114, 132-132	2.2	5
82	The Combination of Romidepsin and Bortezomib Results in Synergistic Induction of Apoptosis in Human B-Lymphoma Cell Lines.. <i>Blood</i> , <b>2009</b> , 114, 1689-1689	2.2	1
81	Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ).. <i>Blood</i> , <b>2009</b> , 114, 1827-1827	2.2	1
80	Inhibition of the Proteasome in Bone Marrow-Derived CD138+ Tumor Cells Following Carfilzomib Administration in Relapsed or Refractory Myeloma Patients.. <i>Blood</i> , <b>2009</b> , 114, 1845-1845	2.2	1
79	Alkaline Phosphatase (ALP) Variation During Carfilzomib Treatment Is Associated to Best Response in Multiple Myeloma.. <i>Blood</i> , <b>2009</b> , 114, 2865-2865	2.2	2
78	Neutropenia Is a Predictable and Early Event in Affected Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide in Combination with Dexamethasone.. <i>Blood</i> , <b>2009</b> , 114, 2879-2879	2.2	5
77	Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.. <i>Blood</i> , <b>2009</b> , 114, 3890-3890	2.2	2
76	Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects.. <i>Blood</i> , <b>2009</b> , 114, 430-430	2.2	10
75	Autologous Hematopoietic Stem Cell Transplantation (HCT) is a Safe and Effective Treatment for Primary Plasma Cell Leukemia: The CIBMTR Experience.. <i>Blood</i> , <b>2009</b> , 114, 532-532	2.2	5
74	The Use of An Online Case Database to Obtain Clinical and Psychosocial Information Related to the Selection of and Experience with Initial Systemic Therapy for Multiple Myeloma.. <i>Blood</i> , <b>2009</b> , 114, 1408-1408	2.2	108
73	Thromboembolic Events (TEE) with Lenalidomide-Based Therapies for Multiple Myeloma (MM): Emory Experience.. <i>Blood</i> , <b>2009</b> , 114, 3888-3888	2.2	1



72	Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Myeloma (MM) - Chronic Graft Versus Host Disease (GVHD) is Associated with Lower Risk of Relapse and Superior Progression Free Survival (PFS) - A CIBMTR Analysis.. <i>Blood</i> , <b>2009</b> , 114, 53-53	2.2	
71	A Phase I Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma.. <i>Blood</i> , <b>2009</b> , 114, 3851-3851	2.2	
70	A Randomized Clinical Trial Comparing Cytokine Administration Sites for Mobilization of Peripheral Hematopoietic Progenitor Cells for Patients with Hematological Malignancies Undergoing Autologous Stem Cell Transplantation.. <i>Blood</i> , <b>2009</b> , 114, 4230-4230	2.2	
69	Preliminary Results of a Phase I Study of the Pan-PI3 Kinase Inhibitor SF1126 in Patients with Relapsed and Refractory Myeloma.. <i>Blood</i> , <b>2009</b> , 114, 3879-3879	2.2	
68	Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , <b>2008</b> , 143, 222-229	4.5	81
67	Regulation of alloimmune responses by dendritic cell subsets. <i>Experimental Hematology</i> , <b>2008</b> , 36, 1309-1317	3.7	11
66	Multiple myeloma presenting with advanced renal failure: a case report and new treatment options. <i>Clinical Lymphoma and Myeloma</i> , <b>2008</b> , 8, 52-4		10
65	Practical considerations for multiple myeloma: an overview of recent data and current options. <i>Clinical Lymphoma and Myeloma</i> , <b>2008</b> , 8 Suppl 4, S144-8		1
64	Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4784-90	2.2	227
63	Eliminating the complete response penalty from myeloma response assessment. <i>Blood</i> , <b>2008</b> , 111, 3297-32	8.2	14
62	Clinical uses of GM-CSF, a critical appraisal and update. <i>Biologics: Targets and Therapy</i> , <b>2008</b> , 2, 13-27	4.4	48
61	Review of peripheral neuropathy in plasma cell disorders. <i>Hematological Oncology</i> , <b>2008</b> , 26, 55-65	1.3	52
60	Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.. <i>Blood</i> , <b>2008</b> , 112, 1742-1742	2.2	10
59	A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.. <i>Blood</i> , <b>2008</b> , 112, 3332-3332	2.2	1
58	Safety and Efficacy Outcomes with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma Were Not Significantly Different for the Treatment of Patients with or without High-Risk Disease or Elderly Status. <i>Blood</i> , <b>2008</b> , 112, 3701-3701	2.2	3
57	A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2008</b> , 112, 3706-3706	2.2	6
56	FGFR3 Associates with and Tyrosine-Phosphorylates p90RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation. <i>Blood</i> , <b>2008</b> , 112, 3722-3722	2.2	1
55	Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib. <i>Blood</i> , <b>2008</b> , 112, 870-870	2.2	15

54	Maintenance Therapy in Multiple Myeloma <b>2008</b> , 91-98		1
53	Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study. <i>Blood</i> , <b>2008</b> , 112, 3644-3644		2,2
52	Higher Numbers of Circulating Dendritic Cells and T-Cells Predict Response to Extracorporeal Photopheresis in Patients with Chronic Graft-Versus-Host Disease. <i>Blood</i> , <b>2008</b> , 112, 1183-1183	2.2	
51	Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 2133-42	59.2	1057
50	Maintenance therapy in lymphoma. <i>Clinical Lymphoma and Myeloma</i> , <b>2007</b> , 7, 507-13		21
49	Multiple myeloma: novel approaches for relapsed disease. <i>Clinical Lymphoma and Myeloma</i> , <b>2007</b> , 8 Suppl 1, S18-23		4
48	Racial differences in the incidence and outcomes for patients with hematological malignancies. <i>Current Problems in Cancer</i> , <b>2007</b> , 31, 182-201	2.3	22
47	Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , <b>2007</b> , 137, 429-35	4.5	103
46	Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. <i>Transfusion</i> , <b>2007</b> , 47, 629-35	2.9	16
45	PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. <i>Future Oncology</i> , <b>2007</b> , 3, 639-47	3.6	65
44	Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. <i>Blood</i> , <b>2007</b> , 110, 3557-60	2.2	443
43	Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. <i>Blood</i> , <b>2007</b> , 109, 2604-6	2.2	215
42	Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation.. <i>Blood</i> , <b>2007</b> , 110, 1165-1165	2.2	14
41	Combination of Bortezomib with Tipifarnib (R115777) Induces Synergistic Myeloma Cell Apoptosis Via Down-Regulation of HDAC6 and Inhibition of Aggresome Formation.. <i>Blood</i> , <b>2007</b> , 110, 1520-1520	2.2	2
40	Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.. <i>Blood</i> , <b>2007</b> , 110, 187-187	2.2	6
39	Bortezomib, Thalidomide, and Dexamethasone as Induction Therapy for Patients with Symptomatic Multiple Myeloma.. <i>Blood</i> , <b>2007</b> , 110, 3605-3605	2.2	1
38	Impact of Prior Lenalidomide Treatment on Peripheral Blood Stem Cell (PBSC) Mobilization in Untreated Multiple Myeloma (MM) Patients.. <i>Blood</i> , <b>2007</b> , 110, 3612-3612	2.2	1
37	A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.. <i>Blood</i> , <b>2007</b> , 110, 949-949	2.2	3

36	p90RSK2 as a Therapeutic Target in Treatment of FGFR3-Expressing t(4;14) Multiple Myeloma.. <i>Blood</i> , <b>2007</b> , 110, 253-253	2.2	
35	The Effect of Rituximab on Mobilization with AMD3100 Plus G-CSF in Patients with Relapsed or Refractory NHL or HD.. <i>Blood</i> , <b>2007</b> , 110, 1912-1912	2.2	
34	Targeting 14-3-3 Sensitizes Native and Mutant BCR-ABL to Inhibition with U0126, Rapamycin and Bcl-2 Inhibitor GX15-070.. <i>Blood</i> , <b>2007</b> , 110, 2920-2920	2.2	
33	Novel treatment approaches for patients with relapsed and refractory multiple myeloma. <i>Current Treatment Options in Oncology</i> , <b>2006</b> , 7, 246-57	5.4	2
32	Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. <i>Cancer</i> , <b>2006</b> , 106, 2171-80	6.4	40
31	Proteasome inhibition: novel therapy for multiple myeloma. <i>Oncology Research and Treatment</i> , <b>2006</b> , 29, 162-8	2.8	5
30	Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 4867-74	2.2	600
29	Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma. <i>Leukemia and Lymphoma</i> , <b>2006</b> , 47, 2155-62	1.9	9
28	Novel treatment approaches for patients with multiple myeloma. <i>Clinical Lymphoma and Myeloma</i> , <b>2006</b> , 6, 281-8		4
27	When the same is really different <i>Blood</i> , <b>2006</b> , 108, 3233-3234	2.2	1
26	T Cell Reconstitution in First 200 Days Post Transplantation Predicts Long Term Survival in Allogeneic Hematopoietic Progenitor Cell Transplantation (HPCT).. <i>Blood</i> , <b>2006</b> , 108, 3224-3224	2.2	1
25	A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM).. <i>Blood</i> , <b>2006</b> , 108, 406-406	2.2	19
24	Infliximab for the Treatment of Chronic Graft Versus Host Disease.. <i>Blood</i> , <b>2006</b> , 108, 2889-2889	2.2	
23	Tolerability and Anti-Leukemic Activity of Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] in Advanced MDS and AML: Interim Analysis of Phase I/II Data.. <i>Blood</i> , <b>2006</b> , 108, 1960-1960	2.2	
22	Impact of Revised International Working Group Criteria on Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.. <i>Blood</i> , <b>2006</b> , 108, 3065-3065	2.2	
21	Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 2487-98	59.2	2097
20	The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. <i>Blood</i> , <b>2005</b> , 106, 4322-9	2.2	52
19	Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. <i>Blood</i> , <b>2005</b> , 106, 3777-84	2.2	278

18	Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): evidence of antitumour activity. <i>Expert Opinion on Biological Therapy</i> , <b>2005</b> , 5, 293-311	5.4	18
17	Combination of Farnesyl Transferase Inhibitor (Tipifarnib) with Perifosine Induces Apoptosis through phos-PDK1 in Human Lymphoma and Leukemia Cell Lines.. <i>Blood</i> , <b>2005</b> , 106, 1488-1488	2.2	1
16	Combination of Akt/PKB Inhibition (Perifosine) and Farnesyl Transferase Inhibition (Tipifarnib) Results in Increased Cell Death in Myeloma Cells Lines.. <i>Blood</i> , <b>2005</b> , 106, 1568-1568	2.2	1
15	Patient Characteristics in CD 20+ and CD 20- Adult Acute Lymphoblastic Leukemia (ALL): A Single Institution Analysis.. <i>Blood</i> , <b>2005</b> , 106, 4523-4523	2.2	
14	Relapse Free Survival of Elderly AML Patients Is Comparable to That of Younger Adults When Treated with a Modified Dose Intensive Cytarabine Regimen.. <i>Blood</i> , <b>2005</b> , 106, 4634-4634	2.2	
13	Decreased Incidence of Relapse in Patients with Acute Leukemia Transplanted from Matched Unrelated Donors: Induction of GvL.. <i>Blood</i> , <b>2005</b> , 106, 2016-2016	2.2	
12	A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. <i>Biology of Blood and Marrow Transplantation</i> , <b>2004</b> , 10, 848-57	4.7	38
11	A Phase I Trial of Ara-C, Topotecan, and Gemtuzumab Ozogamicin (Mylotarg) for Advanced MDS and Secondary or Relapsed AML.. <i>Blood</i> , <b>2004</b> , 104, 1814-1814	2.2	2
10	Donor Dendritic Cells Regulate Immune Reconstitution after Allogeneic Bone Marrow Transplantation.. <i>Blood</i> , <b>2004</b> , 104, 3073-3073	2.2	
9	Predictors of More Rapid Lymphoid Reconstitution after Allogeneic Transplantation.. <i>Blood</i> , <b>2004</b> , 104, 3159-3159	2.2	
8	Signal transduction and myeloma: new targets, new hope. <i>Cancer Biology and Therapy</i> , <b>2003</b> , 2, 310-9	4.6	10
7	Breakthroughs in the management of multiple myeloma. <i>Drugs</i> , <b>2003</b> , 63, 1621-36	12.1	10
6	Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. <i>Blood</i> , <b>2001</b> , 97, 2948-56	2.2	119
5	Changes in the pattern of TCR V beta repertoire expression after bone marrow transplant is linked to the HLA haplotype in humans. <i>British Journal of Haematology</i> , <b>2001</b> , 113, 224-30	4.5	5
4	Treatment of emergent peripheral neuropathy in plasma cell disorders245-254		
3	MAINTENANCE THERAPY IN MULTIPLE MYELOMA37-45		
2	Multiple myeloma immunoglobulin $\kappa$ translocations portend poor prognosis		1
1	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. <i>Blood Cancer Discovery</i> , OF1-OF12	7	2

